243 related articles for article (PubMed ID: 29528075)
1. Recent advances in anti-angiogenic nanomedicines for cancer therapy.
Bhattarai P; Hameed S; Dai Z
Nanoscale; 2018 Mar; 10(12):5393-5423. PubMed ID: 29528075
[TBL] [Abstract][Full Text] [Related]
2. Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment.
Hameed S; Bhattarai P; Dai Z
Sci China Life Sci; 2018 Apr; 61(4):380-391. PubMed ID: 29607461
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicines Targeting the Tumor Microenvironment.
Tong R; Langer R
Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
[TBL] [Abstract][Full Text] [Related]
4. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
5. Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer.
Mukherjee A; Madamsetty VS; Paul MK; Mukherjee S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936832
[TBL] [Abstract][Full Text] [Related]
6. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.
Linton SS; Sherwood SG; Drews KC; Kester M
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016; 8(2):208-22. PubMed ID: 26153136
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in nanomedicine for enhanced cancer chemotherapy.
Wei G; Wang Y; Yang G; Wang Y; Ju R
Theranostics; 2021; 11(13):6370-6392. PubMed ID: 33995663
[TBL] [Abstract][Full Text] [Related]
8. Combination antitumor therapy with targeted dual-nanomedicines.
Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
[TBL] [Abstract][Full Text] [Related]
9. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
Danhier F; Feron O; Préat V
J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419
[TBL] [Abstract][Full Text] [Related]
10. Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy.
Xiao M; Shi Y; Jiang S; Cao M; Chen W; Xu Y; Xu Z; Wang K
Front Oncol; 2022; 12():1039378. PubMed ID: 36523993
[TBL] [Abstract][Full Text] [Related]
11. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
12. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
13. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment.
Marech I; Leporini C; Ammendola M; Porcelli M; Gadaleta CD; Russo E; De Sarro G; Ranieri G
Cancer Lett; 2016 Sep; 380(1):216-26. PubMed ID: 26238184
[TBL] [Abstract][Full Text] [Related]
14. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.
Hussain Z; Khan S; Imran M; Sohail M; Shah SWA; de Matas M
Drug Deliv Transl Res; 2019 Jun; 9(3):721-734. PubMed ID: 30895453
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment.
Jasim SA; Farber IM; Noraldeen SAM; Bansal P; Alsaab HO; Abdullaev B; Alkhafaji AT; Alawadi AH; Hamzah HF; Mohammed BA
Microvasc Res; 2024 Jul; 154():104691. PubMed ID: 38703993
[TBL] [Abstract][Full Text] [Related]
16. Current strategies and future directions of antiangiogenic tumor therapy.
Zhang ZL; Wang JH; Liu XY
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202
[TBL] [Abstract][Full Text] [Related]
17. Engineered Nanoparticles for Effective Redox Signaling During Angiogenic and Antiangiogenic Therapy.
Nethi SK; Barui AK; Mukherjee S; Patra CR
Antioxid Redox Signal; 2019 Feb; 30(5):786-809. PubMed ID: 29943661
[TBL] [Abstract][Full Text] [Related]
18. Nanotechnological strategies for therapeutic targeting of tumor vasculature.
Ding Y; Li S; Nie G
Nanomedicine (Lond); 2013 Jul; 8(7):1209-22. PubMed ID: 23837858
[TBL] [Abstract][Full Text] [Related]
19. Tumor vasculature-targeting nanomedicines.
Zhang Y; He J
Acta Biomater; 2021 Oct; 134():1-12. PubMed ID: 34271167
[TBL] [Abstract][Full Text] [Related]
20. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy.
Hussain Z; Rahim MA; Jan N; Shah H; Rawas-Qalaji M; Khan S; Sohail M; Thu HE; Ramli NA; Sarfraz RM; Abourehab MAS
J Control Release; 2021 Jul; 335():130-157. PubMed ID: 34015400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
